<DOC>
	<DOCNO>NCT00862641</DOCNO>
	<brief_summary>This study intend determine safety tolerance regadenoson subject asthma chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>A Study Safety Tolerance Regadenoson Subjects With Asthma Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<criteria>Subject asthma stable chronic obstructive pulmonary disease ( COPD ) . Subject diagnosis coronary artery disease ( CAD ) risk factor CAD determine current medical diagnosis least 2 follow condition : Type 2 diabetes , hypertension , hypercholesterolemia , current history cigarette smoking ( minimum 10 packyears exposure ) obesity Body Mass Index ( BMI &gt; 30 ) . Subject must abstain smoke 3 hour prior 8 hour post study drug administration . Subject must abstain intake food beverage contain methylated xanthine derivative ( i.e . caffeine , theobromine , methylxanthine ) within 12 hour prior study drug administration FollowUp visit , food may reduce effect regadenoson . Subject able safely abstain theophylline 12 hour prior Day 1 visit , determine Investigator Asthma subject 's frequency severity symptom remain unchanged within 30 day prior study drug administration Asthma subject FEV1 ≥60 % predict COPD subject FEV1/FVC &lt; 0.70 Female subject pregnant , lactate childbearing potential refuse use medically acceptable form contraception FollowUp visit complete . Subject start course corticosteroid , steroid combination longacting Beta2agonist ( LABA ) ( oral inhale ) anticholinergic , undergone change dose medication ≤ 30 day prior study drug administration ( subject stable dose medication &gt; 30 day prior study drug administration allow ) . Subject start leukotriene antagonist ( e.g. , montelukast ) , cromones ( e.g. , cromolyn sodium ) 5lipoxygenase antagonist ( e.g . zileuton zyflo ) undergone change dose medication drug class ≤ 7 day prior study drug administration ( subject stable dose medication &gt; 7 day prior study drug administration allow ) . Subject history second third degree heart block sinus node dysfunction unless subject functioning pacemaker . Subject symptomatic hypotension ( temporary reversible condition longer exist allow ) . Subject allergic intolerant aminophylline . Subject respiratory infection within 2 week prior randomization . Subject surgery within 3 month prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>regadenoson</keyword>
	<keyword>CVT 3146</keyword>
	<keyword>asthma</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>pulmonary disease , chronic obstructive</keyword>
</DOC>